Table 5.
Adjusted effect size by duration of follow-up
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 | Model 7 | Model 8 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N | % | Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | Coefficient (95% CI) | |
| Const | 0.784 (0.703; 0.865) | 0.624 (0.508; 0.740) | 0.653 (0.562; 0.744) | 0.639 (0.535; 0.742) | 0.696 (0.555; 0.838) | 0.612 (0.454; 0.77) | 0.616 (0.463; 0.768) | |||
| Measures | ||||||||||
| SG | 20 | 8.6 | ||||||||
| VAS | 81 | 34.6 | 0.037 (−0.021; 0.095) | 0.067 (−0.048; 0.182) | 0.06 (−0.038; 0.158) | 0.063 (−0.041; 0.168) | 0.072 -0.038; 0.182) | 0.066 (−0.059; 0.191) | 0.073 (−0.060; 0.207) | 0.535 (0.425; 0.645) |
| TTO | 20 | 8.6 | 0.151 (0.098; 0.203) | 0.209 (0.086; 0.331) | 0.180 (0.097;0.264) | 0.191 (0.096; 0.285) | 0.199 (0.091; 0.307) | 0.207 (0.080; 0.334) | 0.213 (0.079; 0.348) | 0.555 (0.377; 0.733) |
| 15D | 2 | 0.9 | 0.017 (−0.059; 0.094) | 0.069 (−0.072; 0.211) | 0.040 (−0.064; 0.144) | 0.065 (−0.063; 0.193) | 0.064 (−0.054; 0.182) | 0.067 (−0.072; 0.205) | 0.076 (−0.076; 0.227) | 0.493 (0.335; 0.651) |
| SF6D | 7 | 3 | 0.171 (0.11; 0.231) | 0.214 (0.077; 0.350) | 0.189 (0.095; 0.283) | 0.199 (0.093; 0.306) | 0.201 (0.095; 0.307) | 0.201 (0.078; 0.325) | 0.217 (0.074; 0.360) | 0.613 (0.455; 0.771) |
| HUI | 31 | 13.3 | −0.052 (−0.127; 0.022) | −0.042 (−0.178; 0.093) | −0.055 (−0.159; 0.049) | −0.044 (−0.159; 0.072) | −0.041 (−0.153; 0.071) | −0.052 (−0.180; 0.076) | −0.04 (−0.187; 0.106) | 0.319 (0.173; 0.465) |
| EQ5D | 73 | 31.2 | 0.114 (0.048; 0.179) | 0.124 (−0.006; 0.254) | 0.113 (0.016; 0.210) | 0.124 (0.015; 0.234) | 0.125 (0.021; 0.229) | 0.116 (−0.005; 0.237) | 0.127 (−0.015; 0.268) | 0.541 (0.407; 0.676) |
| Length of ART | ||||||||||
| Length of ART _1 | −0.148 (−0.274; −0.021) | |||||||||
| Length of ART _2 | 0.397 (0.034; 0.760) | |||||||||
| Study design | ||||||||||
| Cross-sectional | 123 | 52.6 | ||||||||
| Longitudinal | 111 | 47.4 | 0.033 (−0.027; 0.092) | |||||||
| Disease stages | ||||||||||
| Asymptomatic | 22 | 9.4 | ||||||||
| Symptomatic | 41 | 17.5 | −0.017 (−0.094; 0.059) | −0.025 (−0.084; 0.034) | ||||||
| AIDS | 67 | 28.6 | −0.173 (−0.261; −0.086) | −0.176 (−0.278; −0.075) | ||||||
| Mixed group | 104 | 44.4 | −0.061 (−0.120; −0.002) | −0.057 (−0.124; 0.009) | ||||||
| Treatment | ||||||||||
| Non ART | 63 | 26.9 | ||||||||
| ART | 150 | 64.1 | −0.076 (−0.150; −0.002) | −0.067 (−0.170; 0.036) | ||||||
| Combined | 21 | 9 | −0.015 (−0.074; 0.045) | 0.025 (−0.016; 0.066) | ||||||
| Setting | ||||||||||
| Developed | 182 | 77.8 | ||||||||
| Developing | 52 | 22.2 | −0.082 (−0.163; −0.001) | −0.094 (−0.216; 0.029) | −0.087 (−0.187; 0.012) | |||||
| Year | ||||||||||
| 2000/4 | 38 | 16.2 | ||||||||
| 2005/9 | 149 | 63.7 | −0.023 (−0.074; 0.029) | −0.017 (−0.094; 0.059) | 0.196 (0.067; 0.325) | |||||
| 2010/3 | 47 | 20.1 | 0.039 (−0.036; 0.115) | 0.014 (−0.036; 0.064) | 0.248 (0.064; 0.431) |
Figures in bold: p-values<0.05.